American journal of nuclear medicine and molecular imaging最新文献

{"title":"First evaluation of [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ for imaging VEGFR-3 in ovarian cancer patients.","authors":"Xi Chen, Fei Li, Yao Si, Liping Han, Xiaoding Lou, Ling Xi, Jun Dai","doi":"10.62347/FYYB3942","DOIUrl":"10.62347/FYYB3942","url":null,"abstract":"<p><p>To evaluate the safety and VEGFR-3 imaging effects of [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ in ovarian cancer patients. 13 patients with ovarian cancer were recruited and underwent radionuclide imaging with [⁶⁸Ga]Ga-NOTA-(TMVP1)₂. The safety of [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ was assessed in vivo (including vital signs, biochemical indices, ECG, allergic reactions, etc.) and its imaging effect on VEGFR-3 was explored. A total of 1 patient with primary ovarian cancer and 12 patients with recurrent ovarian cancer, with an age range of 41-54 years, were included in the study. 13 ovarian cancer patients had a total of 49 ¹⁸F-FDG-positive lesions, 63.3% of which were positive for [⁶⁸Ga]Ga-NOTA-(TMVP1)₂. The higher expression of VEGFR-3 in [⁶⁸Ga]Ga-NOTA-(TMVP1)₂-positive ovarian cancer lesions was found by immunohistochemical staining, which was positively correlated. Meanwhile, [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ is a safe radiotracer as no significant side effects have been found in the human. In conclusion, [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ enables precise molecular imaging of VEGFR-3 in ovarian cancer patients with a favourable safety profile, providing a new tool for the in vivo assessment of VEGFR-3 in ovarian cancer.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 2","pages":"65-73"},"PeriodicalIF":2.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multivalent FAPI-based radiopharmaceuticals in PET/CT: from cancer diagnostics to theranostics.","authors":"Taoqian Zhao, Steven H Liang","doi":"10.62347/TUZI7617","DOIUrl":"10.62347/TUZI7617","url":null,"abstract":"<p><p>Radiopharmaceuticals targeting fibroblast activation protein (FAP) have rapidly emerged as innovative agents for cancer imaging and therapy. By selectively binding to cancer-associated fibroblasts (CAFs), radiolabeled FAP inhibitors (FAPIs) enable high-contrast PET/CT imaging across diverse tumor types. This article highlights recent advances in FAPI PET/CT imaging, with particular focus on the influence of multivalency effect in radiotracer development.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 2","pages":"82-86"},"PeriodicalIF":1.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma.","authors":"Chongjiao Li, Qilong Hu, Steven H Liang","doi":"10.62347/VHYY2134","DOIUrl":"10.62347/VHYY2134","url":null,"abstract":"<p><p>Clear cell renal cell carcinoma (ccRCC), accounting for 65%-70%, is the most common subtype of renal cell cancers. Contrast-enhanced CT and MRI are still the predominant diagnostic modalities for renal carcinoma in clinical practice, but they cannot provide accurate diagnosis and staging, and molecular information related to tumor microenvironment. Carbonic anhydrase IX (CAIX), a transmembrane metalloenzyme on the cell surface and associated with hypoxia within the tumor, is emerging as a potential molecular target for both diagnosis and therapy in ccRCC. CAIX-targeted molecular imaging enables non-invasive visualization of ccRCC and guides treatment decision-making.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 1","pages":"37-43"},"PeriodicalIF":2.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic parameters analysis of ¹⁸F-FDG PET/CT in the diagnosis and differential diagnosis of collecting duct carcinoma.","authors":"Yongkang Qiu, Xiaoyue Zhang, Jia Cheng, Wenpeng Huang, Zhao Chen, Lele Song, Qi Yang, Xinyao Sun, Aixiang Wang, Tianyao Wang, Lei Kang","doi":"10.62347/KQJB5668","DOIUrl":"10.62347/KQJB5668","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to explore the diagnostic performance of ¹⁸F-FDG PET/CT in distinguishing collecting duct carcinoma (CDC) from clear cell renal cell carcinoma (ccRCC).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 11 patients with CDC and 27 patients with ccRCC who underwent ¹⁸F-FDG PET/CT examinations. Clinical indicators and the SUVmax, tumor-to-liver standardized uptake value ratio (TLR), tumor-to-kidney standardized uptake value ratio (TKR), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) values of the primary tumor, whole-body MTV (WBMTV), and whole-body TLG (WBTLG) based on a baseline PET scan, were recorded and compared between the two groups. To assess the discriminative power of these metabolic parameters between CDC and ccRCC, we performed a receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>The median age of the 11 CDC patients was 59 years. All CDC patients were in advanced stages (18% stage III and 82% stage IV). Compare with ccRCC patients, CDC patients had higher lymph node metastases rates (72.7% vs. 22.2%, <i>P</i> = 0.008) and distant metastases rates (81.8% vs. 22.2%, <i>P</i> = 0.001). The primary tumor in CDC also showed higher SUVmax (10.5 vs. 4.0, <i>P</i> < 0.001), TLR (3.9 vs. 1.4, <i>P</i> < 0.001), TKR (4.4 vs. 1.5, <i>P</i> < 0.001), MTV (53.2 vs. 9.5, <i>P</i> = 0.021), and TLG (305.7 vs. 30.4, <i>P</i> = 0.0069) than ccRCC. The WBMTV and WBTLG of CDC patients were also higher than the ccRCC group (144.1 vs. 9.5, <i>P</i> = 0.0013 and 528.4 vs. 30.4, <i>P</i> = 0.0013, respectively). ROC curve analysis revealed no significant differences in the ability of SUVmax, TLR and TKR to differentiate CDC from ccRCC. Median survival for CDC was 36 months, worse for older patients.</p><p><strong>Conclusion: </strong>The utilization of ¹⁸F-FDG PET/CT can assist to detect the metastases and provide guidance for diagnosis and staging. Metabolic parameters obtained from ¹⁸F-FDG PET/CT hold promise for distinguishing CDC from ccRCC.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 1","pages":"28-36"},"PeriodicalIF":2.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research process of PET tracers for neuroendocrine tumors diagnosis.","authors":"Xiangyuan Bao, Shuai Li, Shaobo Yao, Qiusong Chen","doi":"10.62347/JXLY1661","DOIUrl":"10.62347/JXLY1661","url":null,"abstract":"<p><p>Neuroendocrine tumors (NETs) can affect several organ systems and present a variety of clinical symptoms, which are difficult to diagnose by conventional methods. Somatostatin receptor (SSTR) is a group of specific receptors expressed on the well-differentiated NET cell membrane. [⁶⁸Ga]-labeled somatostatin analogues (SSAs) PET/CT, endogenous ligands targeting SSTR, is widely used in currently clinical NETs diagnosis. The dual-tracer strategy ([⁶⁸Ga]Ga-SSAs + [¹⁸F]FDG) allows for a more detailed evaluation of tumor metabolism and receptor expression. The NETPET score, integrating [⁶⁸Ga]Ga-SSAs PET/CT and [¹⁸F]FDG PET/CT results, enhances the accuracy of predicting treatment response and prognosis. In addition, novel isotopes ([¹⁸F]/[⁶⁴Cu]) labeled SSAs and SSTR antagonists outperformed [⁶⁸Ga]-SSAs in lesion detection, tumor uptake, and tumor-to-background ratio. Due to undifferentiated or dedifferentiated NETs, SSTR may not be expressed. [⁶⁸Ga]Ga-Pentixafor and [¹⁸F]-FDG PET/CT are applicable for SSTR-negative NET diagnosis. [¹⁸F]-MFBG and [¹⁸F]-DOPA have a higher sensitivity for identifying non-metastatic pheochromocytoma and paraganglioma (PPGL) than other radiotracers. This review addressed NET diagnosis with conventional imaging techniques, the clinical application of novel radiotracers, and the merits and limitations of the various radiotracers.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 1","pages":"1-14"},"PeriodicalIF":2.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of a deep learning-based reconstruction approach utilizing dual-view projection for myocardial perfusion SPECT imaging.","authors":"Hui Liu, Yajing Zhang, Zhenlei Lyu, Li Cheng, Lilei Gao, Jing Wu, Yaqiang Liu","doi":"10.62347/MLFB9278","DOIUrl":"10.62347/MLFB9278","url":null,"abstract":"<p><p>Single-photon emission computed tomography (SPECT) is widely used in myocardial perfusion imaging (MPI) in clinic. However, conventional dual-head SPECT scanners require lengthy scanning times and gantry rotation, which limits the application of SPECT MPI. In this work, we proposed a deep learning-based approach to reconstruct dual-view projections, aiming to reduce acquisition time and enable non-rotational imaging for MPI based on conventional dual-head SPECT scanners. U-Net was adopted for the dual-view projection reconstruction. Initially, 2D U-Nets were used to evaluate various data organization schemes for dual-view projection as input, including paved projection, interleaved projection, and stacked projection, with and without an attenuation map. Subsequently, we developed 3D U-Nets using the optimal data organization scheme as input to further enhance reconstruction performance. The dataset consisted of a total of 116 SPECT/CT scans with ^99mTc-tetrofosmin tracer acquired on a GE NM/CT 640 scanner. Reconstruction performance was assessed using quantitative metrices and absolute percentage errors, while the reconstruction images from the full-view projection were used as reference images. The 2D U-Nets provided reasonable transverse view images but exhibited slight axial discontinuity compared to the reference images, regardless of the data organization schemes. Incorporating the attenuation map reduced this axial discontinuity. Quantitatively, the 2D U-Net trained using both stacked projection and attenuation map achieved the best performance, with a normalized mean absolute error of 0.6%±0.3% and a structural similarity index measure (SSIM) of 0.93±0.04. The 3D U-Net further improved the performance with less axial discontinuity and a higher SSIM of 0.94±0.03. The localized absolute percentage errors were 1.8±16.8% and -2.0±6.3% in the left ventricular (LV) cavity and myocardium, respectively. We developed a deep learning-based image reconstruction approach for dual-view projection from a conventional SPECT scanner. The 3D U-Net, trained with the stacked projection with an attenuation map is effective for non-rotational imaging and could benefit dynamic myocardium perfusion imaging.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 1","pages":"15-27"},"PeriodicalIF":2.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic progression of primary cutaneous anaplastic large cell lymphoma in ¹⁸F-FDG PET/CT: a case report.","authors":"Jia Cheng, Yongkang Qiu, Lele Song, Jing Wu, Lei Kang","doi":"10.62347/QFCF2923","DOIUrl":"10.62347/QFCF2923","url":null,"abstract":"<p><p>Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a type of skin T-cell lymphoma with a favorable prognosis. Some patients may experience recurrence, but systemic involvement is rare. Some studies suggest that systemic progression is associated with poor prognosis. The value of ¹⁸F-FDG PET/CT in diagnosing lymphoma has been recognized, but there is often controversy over the application value of ¹⁸F-FDG PET/CT in pcALCL. We present a rare case of pcALCL involving multiple systemic lesions, monitored and evaluated using ¹⁸F-FDG PET/CT to assist in clinical treatment decisions. Through this case, we consider that ¹⁸F-FDG PET/CT has significant value in diagnosing pcALCL. However, more clinical cases are needed to confirm whether high FDG uptake is associated with the invasiveness of pcALCL and the impact of high FDG uptake and Ki-67 expression on the progression and prognosis of pcALCL.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 6","pages":"357-364"},"PeriodicalIF":2.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG PET/CT findings in a mucosa-associated lymphoid tissue lymphoma patient coexisting with primary myelofibrosis.","authors":"Yanmei Han, Ruolin Wu, Yajing Zhang, Xiao Zhang, Zairong Gao","doi":"10.62347/BZUZ7442","DOIUrl":"10.62347/BZUZ7442","url":null,"abstract":"<p><p>A 61-year-old male presented with hematemesis and melena. Biopsy and immunohistochemistry confirmed mucosa-associated lymphoid tissue (MALT) lymphoma in the posterior wall of the gastric antrum, prompting further evaluation with ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT). In addition to elevated uptake in the gastric antrum, ¹⁸F-FDG PET/CT showed diffuse uptake in multiple bone marrow, initially suspected to indicate bone marrow involvement by lymphoma. Further examination identified it as primary myelofibrosis (PMF). Following concurrent therapies, ¹⁸F-FDG PET/CT demonstrated negative uptake in gastric antrum, indicating complete remission of the lymphoma, while the elevated bone marrow uptake suggested progression of PMF. The coexistence of MALT lymphoma and PMF is very rare. This case highlights the image characteristics and potential diagnostic and therapeutic monitoring value of ¹⁸F-FDG PET/CT in patients with concurrent MALT lymphoma and PMF.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 6","pages":"365-370"},"PeriodicalIF":2.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.","authors":"Jaskeerat Gujral, Om H Gandhi, Shashi B Singh, Malia Ahmed, Cyrus Ayubcha, Thomas J Werner, Mona-Elisabeth Revheim, Abass Alavi","doi":"10.62347/AICM8774","DOIUrl":"10.62347/AICM8774","url":null,"abstract":"<p><p>This review assesses the primary neuroimaging techniques used to evaluate Parkinson's disease (PD) - a neurological condition characterized by gradual dopamine-producing nerve cell degeneration. The neuroimaging techniques explored include positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). These modalities offer varying degrees of insights into PD pathophysiology, diagnostic accuracy, specificity by way of exclusion of other Parkinsonian syndromes, and monitoring of disease progression. Neuroimaging is thus crucial for diagnosing and managing PD, with integrated multimodal approaches and novel techniques further enhancing early detection and treatment evaluation.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 6","pages":"371-390"},"PeriodicalIF":2.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fully automated radiosynthesis of [¹⁸F]FCPPC for imaging microglia with PET.","authors":"Pritam Roy, Yan Guo, Otto Muzik, Eric A Woodcock, Huailei Jiang","doi":"10.62347/QFGP5253","DOIUrl":"10.62347/QFGP5253","url":null,"abstract":"<p><p>Colony-stimulating factor 1 receptor (CSF1R) is almost exclusively expressed on microglia in the human brain and thus, has promise as a biomarker for imaging microglia density as a proxy for neuroinflammation. [¹¹C]CPPC is a radiotracer with selective affinity to CSF1R, and has been evaluated for in-human microglia PET imaging. The flourine-18 labeled CPPC derivative, 5-cyano-N-(4-(4-(2-[¹⁸F]fluoroethyl)piperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide ([¹⁸F]FCPPC), was previously synthesized, however, with a low radiochemical yield using manual radiosynthesis. In this work, we report a fully automated radiosynthesis of [¹⁸F]FCPPC on a Synthra RNplus research module. In a total synthesis time of 50 min, [¹⁸F]FCPPC was obtained in decay corrected radiochemical yields of 26.8 ± 0.1% (n = 3) with >99% radiochemical purities. Quality control testing showed that [¹⁸F]FCPPC met all release criteria. In sum, we report the first fully automated radiosynthesis of [¹⁸F]FCPPC, a promising radiopharmaceutical for imaging microglia in humans.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 6","pages":"351-356"},"PeriodicalIF":1.8,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}